Study summary

Pembrolizumab plus chemotherapy helps regardless of mismatch-repair status

NRG-GY018 trial · 810 people, phase 3 · Published March 2025, Nature Medicine; FDA approved 2023

What was tested

Pembrolizumab added to chemotherapy, against chemotherapy alone, for advanced or recurrent endometrial cancer, in both mismatch-repair-deficient and -proficient tumors.

What they found

• Time before growth improved in both biomarker groups (hazard ratio 0.45 in dMMR, 0.64 in pMMR tumors).
• Survival trends favored pembrolizumab in both groups, though not yet statistically final.

What it means

Established immunotherapy plus chemotherapy as first treatment for almost everyone with advanced disease, not only dMMR tumors.